Published in Br J Pharmacol on March 01, 1975
Sixth gaddum memorial lecture, National Institute for Medical Research, Mill Hill, January 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol (1977) 6.01
Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc Natl Acad Sci U S A (1983) 3.17
Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci U S A (1979) 2.66
The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol (1977) 2.59
Specific receptor for the opioid peptide dynorphin: structure--activity relationships. Proc Natl Acad Sci U S A (1981) 2.53
Enkephalin inhibits release of substance P from sensory neurons in culture and decreases action potential duration. Proc Natl Acad Sci U S A (1979) 2.47
Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey. Br J Pharmacol (1975) 2.05
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol (1980) 1.95
Antibodies as a means of isolating and characterizing biologically active substances: presence of a non-peptide, morphine-like compound in the central nervous system. Proc Natl Acad Sci U S A (1976) 1.71
alpha-Adrenoceptors in the mouse vas deferens and their effects on its response to electrical stimulation. Br J Pharmacol (1978) 1.61
Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor. Br J Pharmacol (1984) 1.47
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
The effects of morphine on the release of noradrenaline from the mouse vas deferens. Br J Pharmacol (1976) 1.27
Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin. Br J Pharmacol (1981) 1.24
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Depression by morphine of excitatory junction potentials in the vas deferens of the mouse. Br J Pharmacol (1976) 1.14
Action of morphine on the neuro-effector transmission in the guinea-pig ileum and in the mouse vas deferens. J Physiol (1980) 1.07
An electrophysiological analysis of the effects of morphine on the calcium dependence of neuromuscular transmission in the mouse vas deferens. Br J Pharmacol (1980) 1.06
Proceedings: Is morphine inhibition to the twitch response of the mouse vas deferens mediated via noradrenaline? Br J Pharmacol (1975) 1.05
The effect of chronic morphine treatment of excitatory junction potentials in the mouse vas deferens. Br J Pharmacol (1980) 1.01
Comparison of the receptor binding characteristics of opiate agonists interacting with mu- or kappa-receptors. Br J Pharmacol (1978) 0.98
The effects of release and depletion of endogenous noradrenaline on the transmission of impulses in the mouse vas deferens. Br J Pharmacol (1978) 0.92
Interactions of drugs active at opiate receptors and drugs active at alpha 2-receptors on various test systems. Br J Pharmacol (1982) 0.90
Hypotensive and sedative effects of alpha-adrenoceptor agonists: relationship to alpha 1- and alpha 2-adrenoceptor potency. Br J Pharmacol (1981) 0.90
Interactions between morphine and the opioid-like peptides in the rat vas deferens. Br J Pharmacol (1980) 0.88
The inhibitory effects of presynaptic alpha-adrenoceptor agonists on contractions of guinea-pig ileum and mouse vas deferens in the morphine-dependent and withdrawn states produced in vitro. Br J Pharmacol (1979) 0.88
Inhibition of neuroeffector transmission by morphine in the vas deferens of naive and morphine-treated mice. Br J Pharmacol (1980) 0.87
Different effects of current strength on inhibitory responses of the mouse vas deferens to methionine- and leucine-enkephalin. Br J Pharmacol (1979) 0.86
Clonidine and morphine increase [3H]-noradrenaline overflow in mouse vas deferens. Br J Pharmacol (1988) 0.84
Comparison of the cardiovascular effects of meptazinol and naloxone following haemorrhagic shock in rats and cats. Br J Pharmacol (1985) 0.84
Effects of morphine on electrically evoked contractions of the vas deferens in two congeneric rodent species differing in sperm competition intensity. Proc Biol Sci (1999) 0.81
Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem (2012) 0.81
Presynaptic opioid delta-receptors in the rabbit mesenteric artery. J Physiol (1986) 0.81
Effects of divalent cations and normorphine on spontaneous excitatory junction potentials in the mouse vas deferens. Br J Pharmacol (1982) 0.80
Desensitization by noradrenaline of responses to stimulation of pre- and postsynaptic adrenoceptors. Br J Pharmacol (1982) 0.78
Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle. Br J Pharmacol (2000) 0.78
Opioid activity of dermenkephalin analogues in the guinea-pig myenteric plexus and the hamster vas deferens. Br J Pharmacol (1991) 0.78
Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene. Br J Pharmacol (2001) 0.77
Pharmacological differentiation of presynaptic inhibitory alpha-adrenoceptors and opiate receptors in the cat nictitating membrane. Br J Pharmacol (1980) 0.77
The effects of opioid drugs and of lithium on steroidogenesis in rat adrenal cell suspensions. Br J Pharmacol (1979) 0.75
Adrenocorticotrophic hormone fragments mimic the effect of morphine in vitro. Br J Pharmacol (1978) 0.75
Enkephalin-like immunoreactivity in the human male genital tract. J Anat (1982) 0.75
An examination of the putative sigma-receptor in the mouse isolated vas deferens. Br J Pharmacol (1989) 0.75
Genetic heterogeneity of histamine H2-receptors in the mouse vas deferens. Br J Pharmacol (1984) 0.75
Micturition in naive and morphine-dependent rats. Br J Pharmacol (1986) 0.75
Evidence that the novel imidazoline compound FT005 is an alpha(2)-adrenoceptor agonist. Br J Pharmacol (2002) 0.75
The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. 1977. Br J Pharmacol (1997) 0.75
Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br J Pharmacol Chemother (1968) 5.00
Evaluation of mechanisms controlling the release and inactivation of the adrenergic transmitter in the rabbit portal vein and vas deferens. Br J Pharmacol (1972) 4.45
A new example of a morphine-sensitive neuro-effector junction: adrenergic transmission in the mouse vas deferens. Br J Pharmacol (1972) 4.11
Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A (1973) 3.34
Inhibition of post-ganglionic motor transmission in vas deferens by indirectly acting sympathomimetic drugs. J Physiol (1972) 3.22
Agonist and antagonist actions of morphine-like drugs on the guinea-pig isolated ileum. Br J Pharmacol Chemother (1966) 2.67
Transmission to the longitudinal muscle of the guinea-pig vas deferens: The effect of pretreatment with guanethidine. Br J Pharmacol (1974) 1.72
HISTOCHEMICAL CORRELATIONS OF ACETYLCHOLINESTERASE AND CATECHOLAMINES IN POSTGANGLIONIC AUTONOMIC NERVES OF THE CAT, RABBIT, AND GUINEA PIG. J Pharmacol Exp Ther (1965) 1.67
Acceleration of noradrenaline biosynthesis in the guinea-pig vas deferens by potassium. Br J Pharmacol (1970) 1.64
Inhibition of noradrenaline release by lysergic acid diethylamide. Br J Pharmacol (1973) 1.56
Abolition of neurally evoked motor responses of the vas deferens by 6-hydroxydopamine. Eur J Pharmacol (1973) 1.31
Comparative potencies of codeine and its demethylated metabolites after intraventricular injection in the mouse. J Pharmacol Exp Ther (1963) 1.25
Proceedings: Assessment of the agonist and antagonist activities of narcotic analgesic drugs by means of the mouse vas deferens. Br J Pharmacol (1974) 1.10
Assessment of the agonist and antagonist properties of narcotic analgesic drugs by their actions on the morphine receptor in the guinea pig ileum. Adv Biochem Psychopharmacol (1973) 1.01
Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA (2000) 10.40
Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (1975) 10.33
Comparative genomics of the lactic acid bacteria. Proc Natl Acad Sci U S A (2006) 10.24
Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med (1999) 9.26
Endogenous opioid peptides: multiple agonists and receptors. Nature (1977) 8.21
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Comorbidities, complications, and coding bias. Does the number of diagnosis codes matter in predicting in-hospital mortality? JAMA (1992) 5.07
Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br J Pharmacol Chemother (1968) 5.00
Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep (1998) 4.85
The gene for familial polyposis coli maps to the long arm of chromosome 5. Science (1987) 4.48
Evaluation of mechanisms controlling the release and inactivation of the adrenergic transmitter in the rabbit portal vein and vas deferens. Br J Pharmacol (1972) 4.45
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (2001) 4.41
The effects of adrenaline, noradrenaline and isoprenaline on inhibitory alpha- and beta-adrenoceptors in the longitudinal muscle of the guinea-pig ileum. Br J Pharmacol (1970) 4.22
A new example of a morphine-sensitive neuro-effector junction: adrenergic transmission in the mouse vas deferens. Br J Pharmacol (1972) 4.11
The use of an optical brightener in the study of plant structure. Stain Technol (1975) 3.70
Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol (2000) 3.27
Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res (1975) 3.26
Head and neck schwannomas--a 10 year review. J Laryngol Otol (2000) 3.25
The effects of changes in dietary protein on the composition and structure of the liver cell. J Physiol (1947) 3.07
Mode of action of morphine-like drugs on autonomic neuro-effectors. Nature (1968) 3.01
Chronic conditions and risk of in-hospital death. Health Serv Res (1994) 3.00
Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol (1991) 2.89
Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ (1997) 2.87
Agonist and antagonist actions of morphine-like drugs on the guinea-pig isolated ileum. Br J Pharmacol Chemother (1966) 2.67
The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol (1977) 2.59
In vitro models in the study of structure-activity relationships of narcotic analgesics. Annu Rev Pharmacol (1975) 2.47
Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol (2001) 2.45
The effects of hexamethonium, morphine and adrenaline on the output of acetylcholine from the myenteric plexus-longitudinal muscle preparation of the ileum. Br J Pharmacol (1970) 2.43
Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J (1978) 2.41
Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet (1994) 2.35
Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther (2015) 2.34
Use of expiratory CT pulmonary angiography to reduce inspiration and breath-hold associated artefact: contrast dynamics and implications for scan protocol. Clin Radiol (2011) 2.30
Verification of smoking history in patients after infarction using urinary nicotine and cotinine measurements. Br Med J (1979) 2.30
Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. Biochem J (1980) 2.24
Errors in using tobacco withdrawal scale. Tob Control (1998) 2.23
Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol (1971) 2.17
Classification of opioid receptors. Br Med Bull (1983) 2.12
Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol (1999) 2.09
Osteopontin--a molecule for all seasons. QJM (2002) 2.09
Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci (1992) 2.06
Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey. Br J Pharmacol (1975) 2.05
A randomised controlled trial of the effect of the provision of free school milk on the growth of children. J Epidemiol Community Health (1980) 2.04
The phototropin family of photoreceptors. Plant Cell (2001) 2.01
The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn Schmiedebergs Arch Pharmacol (1982) 1.99
Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol (2001) 1.98
A review of the epidemiological evidence for the 'antioxidant hypothesis'. Public Health Nutr (2004) 1.97
Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain. Br J Pharmacol (1982) 1.91
A prokaryotic phytochrome. Nature (1997) 1.91
Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol (2001) 1.90
Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A (1999) 1.89
beta 3: an additional auxiliary subunit of the voltage-sensitive sodium channel that modulates channel gating with distinct kinetics. Proc Natl Acad Sci U S A (2000) 1.89
Purification and properties of enkephalin - the possible endogenous ligand for the morphine receptor. Life Sci (1975) 1.88
An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care (2005) 1.87
Influence of dose and fiber type on respiratory malignancy risk in asbestos cement manufacturing. Am Rev Respir Dis (1979) 1.85
Value of routine chest radiography of psychiatric patients. Br Med J (1980) 1.84
Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest (1994) 1.83
Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol (1997) 1.82
Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain. Br J Pharmacol (1981) 1.80
Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol (1998) 1.79
Incorporation of labelled amino acids into the enkephalins. FEBS Lett (1977) 1.73
Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int (2000) 1.72
Some thoughts on the significance of enkephalin, the endogenous ligand. Life Sci (1975) 1.71
Placental-specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci U S A (2004) 1.69
On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J Antibiot (Tokyo) (1978) 1.67
Acceleration of noradrenaline biosynthesis in the guinea-pig vas deferens by potassium. Br J Pharmacol (1970) 1.64
The physical maps for sequencing human chromosomes 1, 6, 9, 10, 13, 20 and X. Nature (2001) 1.63
Resting and action potentials recorded by the sucrose-gap method in the superior cervical ganglion of the rabbit. J Physiol (1968) 1.61
Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatr Pulmonol (2003) 1.61
Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int (1999) 1.60
Characterization of recombinant phytochrome from the cyanobacterium Synechocystis. Proc Natl Acad Sci U S A (1997) 1.60
Intensive care-management at home: an alternative to institutional care? Age Ageing (2001) 1.58
Lead exposure in a firing range. Am J Public Health (1987) 1.58
Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol (1980) 1.56
In vitro pharmacology of the opioid peptides, enkephalins and endorphins. Eur J Pharmacol (1977) 1.56
Inhibition of noradrenaline release by lysergic acid diethylamide. Br J Pharmacol (1973) 1.56
A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use. Health Technol Assess (2006) 1.53
Characterization of opioid receptors in nervous tissue. Proc R Soc Lond B Biol Sci (1980) 1.52
Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis (2001) 1.52
Lipid infusion in the management of poisoning: a report of 6 canine cases. Vet Rec (2013) 1.51
Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology. Stat Med (2001) 1.50
SnR30: a new, essential small nuclear RNA from Saccharomyces cerevisiae. Nucleic Acids Res (1988) 1.48
Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor. Br J Pharmacol (1984) 1.47
Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr (1995) 1.47
Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu- and delta-receptors. Br J Pharmacol (1980) 1.47
Corneal astigmatism in preschool Native Americans. J Am Optom Assoc (1997) 1.46
The DSM-IV field trial for substance use disorders: major results. Drug Alcohol Depend (1995) 1.46
The utilization of fat by the aglycaemic mammalian heart. J Physiol (1941) 1.46
Comparative analysis of the polycystic kidney disease 1 (PKD1) gene reveals an integral membrane glycoprotein with multiple evolutionary conserved domains. Hum Mol Genet (1997) 1.45
The chemical stain removal properties of 'whitening' toothpaste products: studies in vitro. Br Dent J (2000) 1.43